BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18637402)

  • 1. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
    Goodin S
    Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
    Pronzato P
    Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of epothilones in breast cancer therapy.
    Cianfrocca M
    Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL; Goodin S
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.